06/23/2026 | Press release | Distributed by Public on 06/23/2026 08:10
Lake Street Capital Markets Analyst, Thomas Flaten, initiated coverage of Vivani Medical, Inc. with a BUY rating and price target of $4 (VANI-$4). Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases.